Herman Silljé (1969) obtained his Ph.D. in biotechnology at the University of Utrecht in the Netherlands. He completed a postdoctoral fellowship at the University of Geneva in Switzerland, and worked as a group leader at the Max Planck Institute for Biochemistry in Germany. He was scientific director of Kiadis Pharma, a biopharmaceutical company focused on cell-based immunotherapy that is now listed on the Euronext Amsterdam/Brussels stock exchange market.
During the last 10 years Dr. Silljé has been in charge of the preclinical cardiology laboratory at the UMCG in Groningen and is principal investigator in the division of Experimental Cardiology at the UMCG Cardiology Research Institute.
Dr. Silljé is involved in numerous studies with a focus on inherited cardiomyopathies and heart failure research. Key investigations include the unraveling the PLN-R14del cardiomyopathy disease mechanisms and identification and of heart failure biomarkers.
Investigating and treating phospholamban cardiomyopathy
Stem cell models to unravel the susceptibility and resilience to develop heart failure
Secreted factors in cardiac remodeling provoke tumorigenesis and end organ damage in heart failure
MITOchondrial therapy to increase cardiac FORCE and enhance exercise performance